PIGNATA, SALVATORE ANTONIO
 Distribuzione geografica
Continente #
EU - Europa 1.030
NA - Nord America 961
AS - Asia 272
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 2
SA - Sud America 1
Totale 2.271
Nazione #
US - Stati Uniti d'America 957
IE - Irlanda 311
IT - Italia 280
SE - Svezia 245
CN - Cina 135
SG - Singapore 89
PL - Polonia 46
DE - Germania 45
FR - Francia 38
IN - India 32
FI - Finlandia 20
GB - Regno Unito 13
BE - Belgio 9
VN - Vietnam 8
AT - Austria 5
NL - Olanda 5
CA - Canada 4
ES - Italia 4
ID - Indonesia 4
A1 - Anonimo 3
AU - Australia 2
HK - Hong Kong 2
IR - Iran 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
EU - Europa 1
LT - Lituania 1
MK - Macedonia 1
NO - Norvegia 1
RU - Federazione Russa 1
UA - Ucraina 1
Totale 2.271
Città #
Dublin 309
Chandler 295
Nyköping 176
Singapore 73
Ashburn 67
Princeton 53
Messina 48
Warsaw 46
Beijing 44
Medford 41
Dearborn 35
Des Moines 34
Bremen 33
Jacksonville 29
Ann Arbor 27
Hyderabad 22
Rome 16
Boardman 12
Cambridge 12
Helsinki 11
Los Angeles 11
New York 11
Jinan 10
Brussels 9
Dong Ket 8
Falls Church 8
Shenyang 8
Milan 7
Nanjing 7
Pune 7
Wilmington 7
Fuzhou 6
Hebei 6
Munich 6
Nanchang 6
Redwood City 6
Vittoria 6
Santa Clara 5
Santa Domenica 5
Seattle 5
Taizhou 5
Tianjin 5
Vienna 5
Catania 4
Changsha 4
Hangzhou 4
Jakarta 4
Leeds 4
Ningbo 4
Palermo 4
San Mateo 4
Waverly Hall 4
Zhengzhou 4
Bologna 3
Clifton 3
Haikou 3
Lanzhou 3
London 3
Mislata 3
Parma 3
Selargius 3
Strasbourg 3
Torino 3
Turin 3
Ancona 2
Bari 2
Brescia 2
Brindisi 2
Clearwater 2
Frankfurt am Main 2
Guangzhou 2
Hefei 2
Hong Kong 2
Iasi 2
Leawood 2
Norwalk 2
Nürnberg 2
Osimo 2
Pescara 2
Pleasant Hill 2
Pratola Peligna 2
Ravenna 2
Salerno 2
Santa Teresa Di Riva 2
Vicenza 2
Agliana 1
Angri 1
Ardabil 1
Augusta 1
Bengaluru 1
Bergamo 1
Berlin 1
Birmingham 1
Boulder 1
Brno 1
Castelfranco Di Sopra 1
Castelnuovo Rangone 1
Chaoyang 1
Chengdu 1
Dallas 1
Totale 1.672
Nome #
EMIAGENESIA TIROIDEA, MORBO DI BASEDOW-GRAVES E CARCINOMA DIFFERENZIATO DELLA TIROIDE: UN’ASSOCIAZIONE MOLTO RARA. 196
99mTc-Methoxy-Isobutyl-Isonitrile Scintigraphy Is a Useful Tool for Assessing the Risk of Malignancy in Thyroid Nodules with Indeterminate Fine-Needle Cytology 102
Prognostic Validity of Dual Tracer PET/CT in the PRRT Enrollment of GEP-NET Patients 81
Abnormal 99mTc-MIBI Uptakein left lung mimicking a neoplastic lesion in a young woman with nodular goiter. A rare pitfall of 99mTc-MIBI 80
Association of parathyroid carcinoma and thyroid disorders: A clinical review 75
Peptide Receptor Radionuclide Therapy and Somatostatin 'cold' Analogues Therapy in the Treatment of GEP-NET Patients: Our Center’ Experience 75
Braf V600E and 99m-TC MIBI scintigraphy are usefull diagnostic tools in identifying metastatic differentiated thyroid cancer patients refractory to radioiodine therapy. 72
Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy ina real life scenario 70
Usefulness of PET-CT scan in recurrent thyroid cancer 69
Complete Response in a Pancreatic Nen with Liver Metastasis after PRRT in association with Lanreotide Autogel/depot: Design of the Prelude Study 68
99mTc-methoxy-isobutyl-isonitrile (MIBI) scintigraphy is an useful and cost-effective tool for assessing the risk of malignancy in thyroid nodules with indeterminate fine needle cytology (FNAC) 66
Differentiating malignant from benign thyroid nodules with indeterminate cytology by 99mTc-MIBI scan: A new quantitative method for improving diagnostic accuracy 64
Renal Function Evaluation in PRRT Retreatments 60
A Single Centre Experience with 223-Radium-Dichloride ((RaCl2)-Ra-223) Therapy 59
223RA-dichloride use in patients affected by bone metastases from castration-resistant prostate cancer: single centre experience 58
Complete response in a pancreatic NEN with liver metastasis after PRRT in association with lanreotide autogel/depot 57
Combined BRAFV600Eanalysis and99mTc-MIBI scintigraphy can be a useful diagnostic tool in differentiated thyroid cancer patients with incomplete bio-chemical response to first radioiodine therapy (RAIT): a pilot investigation 56
Axitinib after Sunitinib in metastatic renal cancer: Preliminary results from Italian "Real-World" SAX Study 56
99mTc-Methoxy-Isobutil-Isonitrile (MIBI) scintigraphy is an useful and cost-effective tool for assessing the risk of malignancy in thyroid nodules with indeterminate fine needle cytology (FNAC) 54
Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario 54
un caso di carcinoma delle paratiroidi associato ad adenoma autonomo omolaterale della tiroide 54
Comparing radioiodine abdominal absorbed dose in differentiated thyroid cancer patients undergone thyroid remnant ablation in either levo-thyroxine withdrawal or after rhtsh stimulation 53
Theranosticsin nuclear medicine and oncology 51
BRAFV600E and 99mTc-MIBI scintigraphy are usefull diagnostic tools in identifying metastatic differentiated thyroid cancer patients refractory to radioiodine therapy 50
Prognostic Validity of Dual Tracer PET/CT In The PRRT Enrollment of GEP-NET Patients 47
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients 47
Is dual tracer PET/CT a prognostic biomarker in the PRRT enrollment of GEP-NET patients? 46
PRRT retreatments: renal function evaluation 46
Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer? 45
The sensitivity and positive predictive value (PPV) of I-131-post-therapy whole body scan is higher than serum Tg values in detecting metastases in early stage of differentiated thyroid cancer patients 45
From clinical trials to the front line: Vinflunine for treatment of urothelial cell carcinoma at the National Cancer Institute of Naples 43
Post-operative radioiodine therapy (RaIT) as adjuvant therapy in low–intermediate risk differentiated thyroid cancer 39
The additional value of 18F-FDG PET and MRI in patients with glioma: A review of the literature from 2015 to 2020 38
Very early PSA response to abiraterone in mCRPC patients: A novel prognostic factor predicting overall survival 36
Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: The prospective observational scoop trial results 35
Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223 35
Corrigendum: Pazopanib in metastatic renal cancer: A "real-world" experience at national cancer institute "Fondazione G. Pascale" [Front. Pharmacol., 7, 287, (2016)] doi: 10.3389/fphar.2016.00287 33
Pazopanib in metastatic renal cancer: A "real-world" experience at National Cancer Institute "Fondazione G. Pascale" 31
Undetectable or low (< 1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients 25
null 24
null 23
null 16
Peptide receptor radionuclide therapy plus somatostatin analogues for a neuroendocrine tumour combined and maintenance treatment 16
Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose 15
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra 15
Sequencing radium 223 (RA223) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the daily practice: Preliminary results from a retrospective study in Italian centers 13
Totale 2.393
Categoria #
all - tutte 12.044
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.044


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020177 0 0 0 0 1 32 13 33 10 37 19 32
2020/2021281 19 10 77 10 41 6 10 33 32 12 19 12
2021/2022355 6 35 6 7 21 10 8 28 5 39 48 142
2022/2023996 86 128 48 84 71 90 17 58 369 10 22 13
2023/2024243 20 26 13 28 24 42 16 12 0 27 5 30
2024/2025156 12 30 18 51 45 0 0 0 0 0 0 0
Totale 2.393